All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
CytRx Corp. continued its strategy of cashing in on noncore assets by selling worldwide rights to its molecular chaperone portfolio to privately held Orphazyme ApS, of Copenhagen, Denmark, for a potential $120 million in up-front and milestone payments plus possible royalties.